Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress
October 11 2022 - 03:00AM
Business Wire
- Oral and Poster Presentations to Highlight
Preclinical Research for ARCUS® Gene Editing
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage
gene editing company developing ARCUS®-based ex vivo allogeneic CAR
T and in vivo gene editing therapies, today announced that three
abstracts have been accepted by the European Society of Gene &
Cell Therapy (ESGCT) for one oral and two poster presentations at
the upcoming Congress on October 11-14, 2022, at the Edinburgh
International Conference Centre.
Oral Presentation:
Title: Targeting the hepatitis B cccDNA with a
sequence-specific ARCUS nuclease to eliminate Hepatitis B virus in
vivo Date and Time: Wednesday, October 12, 2022, 8:30 AM -
10:40 AM BST Session Title: Parallel 2a, Vaccine
technologies & infectious diseases Location & Poster
Number: Pentland and Sidlaw, OR14 Presenter: Derek
Jantz, Ph.D., Chief Scientific Officer & Strategy
Poster Presentations:
Title: ARCUS gene editing of Apolipoprotein C3 results in
substantial reduction in serum triglycerides in vivo Date and
Time: Wednesday, October 12, 2022, 7:30 PM - 9:00 PM BST
Session Title: Gene and epigenetic editing Location &
Poster Number: Cromdale Hall, Level 2, Poster# P441
Presenter: Wendy Shoop, Scientist
Title: Specific elimination of m.3243A>G mutant
mitochondrial DNA using mitoARCUS in cultured cells and a novel
xenograft mouse model Date and Time: Thursday, October 13,
2022, 5:30 PM - 7:15 PM BST Session Title: Gene and
epigenetic editing Location & Poster Number: Cromdale
Hall, Level 2, Poster #P422 Presenter: Wendy Shoop,
Scientist
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform. ARCUS is a highly
precise and versatile genome editing platform that was designed
with therapeutic safety, delivery, and control in mind. Using
ARCUS, the Company’s pipeline consists of multiple ex vivo
“off-the-shelf” CAR T immunotherapy clinical candidates and several
in vivo gene editing candidates designed to cure genetic and
infectious diseases where no adequate treatments exist. For more
information about Precision BioSciences, please visit
www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221011005408/en/
Investor Contact: Mei Burris Director, Investor Relations
and Finance Mei.Burris@precisionbiosciences.com
Media Contact: Maurissa Messier Senior Director,
Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Mar 2023 to Mar 2024